vs
NI Holdings, Inc.（NODK）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是NI Holdings, Inc.的1.2倍（$75.5M vs $61.0M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -17.5%），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs -9.5%）
NI Holdings, Inc.是一家总部位于美国的保险控股企业，核心业务为提供财产及意外伤害保险产品，覆盖个人车险、家庭财产险、小型商业保险等品类，服务美国多州的个人消费者及小微企业客户。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
NODK vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.2倍
$61.0M
营收增速更快
PBYI
高出45.2%
-17.5%
两年增速更快
PBYI
近两年复合增速
-9.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $61.0M | $75.5M |
| 净利润 | $-3.2M | — |
| 毛利率 | 30.8% | 69.3% |
| 营业利润率 | -4.7% | 22.7% |
| 净利率 | -5.2% | — |
| 营收同比 | -17.5% | 27.7% |
| 净利润同比 | -132.0% | — |
| 每股收益（稀释后） | $-0.16 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NODKPBYI
| Q4 25 | $61.0M | $75.5M | ||
| Q3 25 | $76.6M | $54.5M | ||
| Q2 25 | $76.1M | $52.4M | ||
| Q1 25 | $71.4M | $46.0M | ||
| Q4 24 | $73.9M | $59.1M | ||
| Q3 24 | $89.0M | $80.5M | ||
| Q2 24 | $87.8M | $47.1M | ||
| Q1 24 | $74.5M | $43.8M |
净利润NODKPBYI
| Q4 25 | $-3.2M | — | ||
| Q3 25 | $-1.7M | $8.8M | ||
| Q2 25 | $-12.1M | $5.9M | ||
| Q1 25 | $6.5M | $3.0M | ||
| Q4 24 | $9.8M | — | ||
| Q3 24 | $-2.7M | $20.3M | ||
| Q2 24 | $-19.6M | $-4.5M | ||
| Q1 24 | $6.4M | $-4.8M |
毛利率NODKPBYI
| Q4 25 | 30.8% | 69.3% | ||
| Q3 25 | 20.5% | 77.7% | ||
| Q2 25 | 8.4% | 76.5% | ||
| Q1 25 | 40.6% | 77.1% | ||
| Q4 24 | 52.7% | 76.4% | ||
| Q3 24 | 20.4% | 63.9% | ||
| Q2 24 | 18.0% | 77.4% | ||
| Q1 24 | 39.9% | 75.5% |
营业利润率NODKPBYI
| Q4 25 | -4.7% | 22.7% | ||
| Q3 25 | -2.4% | 17.6% | ||
| Q2 25 | -20.1% | 12.7% | ||
| Q1 25 | 10.8% | 8.7% | ||
| Q4 24 | 18.7% | 22.6% | ||
| Q3 24 | -3.9% | 27.4% | ||
| Q2 24 | -10.3% | -4.6% | ||
| Q1 24 | 11.9% | -5.3% |
净利率NODKPBYI
| Q4 25 | -5.2% | — | ||
| Q3 25 | -2.2% | 16.2% | ||
| Q2 25 | -15.8% | 11.2% | ||
| Q1 25 | 9.0% | 6.5% | ||
| Q4 24 | 13.3% | — | ||
| Q3 24 | -3.0% | 25.2% | ||
| Q2 24 | -22.3% | -9.6% | ||
| Q1 24 | 8.6% | -11.0% |
每股收益（稀释后）NODKPBYI
| Q4 25 | $-0.16 | $0.26 | ||
| Q3 25 | $-0.08 | $0.17 | ||
| Q2 25 | $-0.57 | $0.12 | ||
| Q1 25 | $0.31 | $0.06 | ||
| Q4 24 | $0.48 | $0.40 | ||
| Q3 24 | $-0.13 | $0.41 | ||
| Q2 24 | $-0.94 | $-0.09 | ||
| Q1 24 | $0.30 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $52.2M | $97.5M |
| 总债务越低越好 | $2.4M | $22.7M |
| 股东权益账面价值 | $240.3M | $130.3M |
| 总资产 | $506.0M | $216.3M |
| 负债/权益比越低杠杆越低 | 0.01× | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资NODKPBYI
| Q4 25 | $52.2M | $97.5M | ||
| Q3 25 | $24.7M | $94.4M | ||
| Q2 25 | $56.8M | $96.0M | ||
| Q1 25 | $57.2M | $93.2M | ||
| Q4 24 | $51.4M | $101.0M | ||
| Q3 24 | $39.1M | $96.7M | ||
| Q2 24 | $51.4M | $96.8M | ||
| Q1 24 | $68.5M | $107.2M |
总债务NODKPBYI
| Q4 25 | $2.4M | $22.7M | ||
| Q3 25 | $2.4M | $34.0M | ||
| Q2 25 | — | $45.3M | ||
| Q1 25 | — | $56.7M | ||
| Q4 24 | $2.4M | $68.0M | ||
| Q3 24 | $2.4M | $79.3M | ||
| Q2 24 | $2.4M | $90.7M | ||
| Q1 24 | $2.4M | $102.0M |
股东权益NODKPBYI
| Q4 25 | $240.3M | $130.3M | ||
| Q3 25 | $243.8M | $115.3M | ||
| Q2 25 | $243.3M | $104.7M | ||
| Q1 25 | $254.0M | $97.1M | ||
| Q4 24 | $244.6M | $92.1M | ||
| Q3 24 | $241.4M | $71.1M | ||
| Q2 24 | $236.1M | $48.5M | ||
| Q1 24 | $255.8M | $51.0M |
总资产NODKPBYI
| Q4 25 | $506.0M | $216.3M | ||
| Q3 25 | $543.8M | $202.9M | ||
| Q2 25 | $620.1M | $194.9M | ||
| Q1 25 | $525.4M | $196.2M | ||
| Q4 24 | $526.5M | $213.3M | ||
| Q3 24 | $559.9M | $220.7M | ||
| Q2 24 | $571.0M | $205.0M | ||
| Q1 24 | $674.5M | $214.1M |
负债/权益比NODKPBYI
| Q4 25 | 0.01× | 0.17× | ||
| Q3 25 | 0.01× | 0.30× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | 0.01× | 0.74× | ||
| Q3 24 | 0.01× | 1.12× | ||
| Q2 24 | 0.01× | 1.87× | ||
| Q1 24 | 0.01× | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.2M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | — | $14.4M |
| 自由现金流率自由现金流/营收 | — | 19.1% |
| 资本支出强度资本支出/营收 | 0.0% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $41.7M |
8季度趋势，按日历期对齐
经营现金流NODKPBYI
| Q4 25 | $13.2M | $14.4M | ||
| Q3 25 | $-44.8M | $9.7M | ||
| Q2 25 | $6.4M | $14.1M | ||
| Q1 25 | $9.9M | $3.6M | ||
| Q4 24 | $21.7M | $15.6M | ||
| Q3 24 | $-18.0M | $11.0M | ||
| Q2 24 | $18.1M | $1.0M | ||
| Q1 24 | $16.7M | $11.2M |
自由现金流NODKPBYI
| Q4 25 | — | $14.4M | ||
| Q3 25 | $-44.8M | $9.7M | ||
| Q2 25 | $6.2M | $14.1M | ||
| Q1 25 | $9.9M | $3.6M | ||
| Q4 24 | $21.5M | $15.6M | ||
| Q3 24 | $-18.1M | $11.0M | ||
| Q2 24 | $17.5M | $1.0M | ||
| Q1 24 | $16.6M | — |
自由现金流率NODKPBYI
| Q4 25 | — | 19.1% | ||
| Q3 25 | -58.6% | 17.7% | ||
| Q2 25 | 8.2% | 26.8% | ||
| Q1 25 | 13.8% | 7.7% | ||
| Q4 24 | 29.1% | 26.4% | ||
| Q3 24 | -20.4% | 13.7% | ||
| Q2 24 | 20.0% | 2.1% | ||
| Q1 24 | 22.3% | — |
资本支出强度NODKPBYI
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.2% | 0.0% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.3% | 0.0% | ||
| Q3 24 | 0.2% | 0.0% | ||
| Q2 24 | 0.7% | 0.0% | ||
| Q1 24 | 0.1% | 0.0% |
现金转化率NODKPBYI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | 1.53× | 1.21× | ||
| Q4 24 | 2.21× | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.60× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
